Cytotoxic and genotoxic effects of megazol, an anti-Chagas' disease drug, assessed by different short-term tests

Biochemical Pharmacology

Volumn 64, Issue 11, 2002, Pages 1617-1627

  Poli, Paola ^a,b   Aline de Mello, Michele ^b   Buschini, Annamaria ^a   Mortara, Renato Arruda ^c   Northfleet de Albuquerque, Cristina ^b   Da Silva, Solange ^c   Rossi, Carlo ^a   Zucchi, Tânia Maria Araújo Domingues ^b  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Anti trypanosomal drug; Comet assay; DNA damage; Mutagenicity; Nitroimidazole; Synergetic effects; Yeast

Indexed keywords

2 AMINO 5 (1 METHYL 5 NITRO 2 IMIDAZOLYL) 1,3,4 THIADIAZOLE; ALKALI; ANTITRYPANOSOMAL AGENT; BLEOMICINA; BLEOMYCIN; CYTOCHROME P450; DOUBLE STRANDED DNA; FUNGAL DNA; SINGLE STRANDED DNA; TOXIN;

ANIMAL CELL; ARTICLE; CELL TYPE; CHAGAS DISEASE; COMET ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; DETOXIFICATION; DNA DAMAGE; DNA REPAIR; DRUG ACTIVITY; DRUG POTENTIATION; DRUG SCREENING; ENZYME ACTIVITY; ENZYME INDUCTION; FUNGAL STRAIN; GENOTOXICITY; IN VITRO STUDY; LEUKOCYTE; MAMMAL CELL; MOUSE; MUTAGENICITY; NONHUMAN; PRIORITY JOURNAL; RAT; RISK BENEFIT ANALYSIS; SACCHAROMYCES CEREVISIAE; TIME; VERO CELL;

ANIMALS; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; CHAGAS DISEASE; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; LEUKOCYTES; MICE; RATS; THIADIAZOLES; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI; VERO CELLS; YEASTS;

EID: 0036889990     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(02)01390-4     Document Type: Article

References (43)

1. Re J.L., De Meo M.P., Laget M., Guiraud H., Castegnaro M., Vanelle P., Dumenil G. Evaluation of the genotoxic activity of metronidazole and dimetridazole in human lymphocytes by the Comet assay. Mutat. Res. 375:1997;147-155.
2. Ferreira R.C., de Melo M.E., Moraes Junior M.A., Ferreira L.C. Evaluation of genotoxic activity in the blood and urine of guinea pigs treated with nifurtimox and benznidazole. Braz. J. Med. Biol. Res. 21:1988;1069-1077.
3. Ferreira R.C., Schwarz U., Ferreira L.C. Activation of anti-Trypanosoma cruzi drugs to genotoxic metabolites promoted by mammalian microsomal enzymes. Mutat. Res. 204:1988;577-583.
4. Sapora O., Paone A., Maggi A., Jenner T.J., O'Neill P. Induction of mutations in V79-4 mammalian cells under hypoxic and aerobic conditions by the cytotoxic 2-nitroimidazole-aziridines, RSU-1069 and RSU-1131. The influence of cellular glutathione. Biochem. Pharmacol. 44:1992;1341-1347.
5. Gupta R.L., Vats V., Juneja T.R. Activation of tinidazole, an antiprotozoal drug to a mutagen by mammalian liver S9. Mutat. Res. 370:1996;195-201.
6. Hrelia P., Murelli L., Paolini M., Cantelli-Forti G. In vivo protective role of antioxidants against genotoxicity of metronidazole and azanidazole. Drugs Exp. Clin. Res. 13:1987;577-583.
7. Yeung T.C., Goldman P. Role of sulfhydryl compounds in the bactericidal effect of metronidazole. Biochem. Pharmacol. 32:1983;3145-3149.
8. Hrelia P., Scotti M., Morotti M., Vigagni F., Paolini M., Sapigni E., Cantelli-Forti G. Dimethylsulfoxide as modifier of the organospecific mutagenicity of metronidazole in mice. Teratog. Carcinog. Mutagen. 10:1990;263-271.
9. De Meo M., Vanelle P., Bernadini E., Laget M., Maldonado J., Jentzer O., Crozet M.P., Dumenil G. Evaluation of the mutagenic and genotoxic activities of 48 nitroimidazoles and related imidazole derivatives by the Ames test and the SOS chromotest. Environ. Mol. Mutagen. 19:1992;167-181.
10. Cantelli-Forti G., Hrelia P., Paolini M., Bronzetti G., Biagi G.L. The organospecific activity of metronidazole and azanidazole in the intrasanguineous host-mediated assay. Drugs Exp. Clin. Res. 11:1985;755-759.
11. Konopacka M., Grzybowska E., Michalska J. Lack of genotoxic activity of metronidazole and P1 derivative in two eukaryotic tests. Pol. J. Pharmacol. Pharm. 42:1990;471-477.
12. Reitz M., Rumpf M., Knitza R. Metronidazole induces DNA strand-breaks in cultures of human lymphocytes and phytohemagglutinin-stimulated human lymphocytes. Arzneimittelforschung. 41:1991;65-69.
13. Reitz M., Rumpf M., Knitza R. DNA single strand-breaks in lymphocytes after metronidazole therapy. Arzneimittelforschung. 41:1991;155-156.
14. Mudry M.D., Carballo M., Labal de Vinuesa M., Gonzalez Cid M., Larripa I. Mutagenic bioassay of certain pharmacological drugs. III. Metronidazole (MTZ). Mutat. Res. 305:1994;127-132.
15. Elizondo G., Gonsebatt M.E., Salazar A.M., Lares I., Santiago P., Herrera J., Hong E., Ostrosky-Wegman P. Genotoxic effects of metronidazole. Mutat. Res. 370:1996;75-80.
16. Fahrig R., Engelke M. Reinvestigation of in vivo genotoxicity studies in man. I. No induction of DNA strand breaks in peripheral lymphocytes after metronidazole therapy. Mutat. Res. 395:1997;215-221.
17. Castro J.A., Diaz de Toranzo E.G. Toxic effects of nifurtimox and benznidazole, two drugs used against American trypanosomiasis (Chagas' disease). Biomem. Environ. Sci. 1:1988;19-33.
18. Gorla N.B. Sister-chromatid exchange in spleenic lymphocytes of mice after exposure to nifurtimox or benznidazole. Mutat. Res. 188:1987;129-133.
19. Tsuhako M.H., Alves M.J., Colli W., Brener Z., Augusto O. Restricted bioreductive metabolism of a nitroimidazole-thiadiazole derivative with curative action in experimental Trypanosoma cruzi infections. Biochem. Pharmacol. 38:1989;4491-4496.
20. Lijinsky W. N-Nitroso compounds in the diet. Mutat. Res. 443:1999;129-138.
21. Viodé C., Bettache N., Cenas N., Krauth-Siegel R.L., Chauvière G., Bakalara N., Périé J. Enzymatic reduction studies of nitroheterocycles. Biochem. Pharmacol. 57:1999;549-557.
22. Ferreira R.C., Ferreira L.C. CL 64,855, a potent anti-Trypanosoma cruzi drug, is also mutagenic in the Salmonella/microsome assay. Mem. Inst. Oswaldo Cruz. 81:1986;49-52.
23. Ferreira R.C., Ferreira L.C. Mutagenicity of CL 64855, a potent anti-Trypanosoma cruzi drug. Mutat. Res. 171:1986;11-15.
24. Li AP, Heflich RH. Genetic Toxicology. Boca Raton (FL): CRC Press; 1991. p. 170-1.
25. Müller L., Kikuchi Y., Probst G., Schechtman L., Shimada H., Sofuni T., Tweats D. ICH-harmonized guidance on genotoxicity testing of pharmaceuticals: evolution, reasoning and impact. Mutat. Res. 436:1999;195-225.
26. Snyder R.D., Green J.W. A review of the genotoxicity of marketed pharmaceuticals. Mutat. Res. 488:2001;151-169.
27. Hartmann A, Suter W. The Comet assay: The test of choice as the second in vivo test for in vitro positive pharmaceuticals. In: Proceedings of International Comet Assay Workshop, Ulm, Germany; 22-24 July 2001.
28. Zimmermann F.K., Kern R., Rosenberg H. A yeast for simultaneous detection of induced mitotic crossing over, mitotic gene conversion and reverse mutation. Mutat. Res. 28:1975;381-388.
29. Procópio D.O., Barros H.C., Mortara R.A. Actin-rich structures formed during the invasion of cultured cells by infective forms of Trypanosoma cruzi. Eur. J. Cell. Biol. 78:1999;911-924.
30. Urbina J.A., Lira R., Visbal G., Bartroli J. In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi. Antimicrob. Agents Chemother. 44:2000;2498-2502.
31. Rossi C., Poli P., Candi A., Buschini A. Modulation of Mitomycin C mutagenicity on Saccharomyces cerevisiae by glutathione, cytochrome P-450, and mitochondria interactions. Mutat. Res. 390:1997;113-120.
32. Poli P., Buschini A., Candi A., Rossi C. Bleomycin genotoxicity alteration by glutathione and cytochrome P-450 content in respiratory proficient and deficient strains of Saccharomyces cerevisiae. Mutagenesis. 14:1999;101-106.
33. Parry EM, Parry JM. The assay of genotoxicity of chemical using the budding yeast Saccharomyces cerevisiae. In: Venitt S, Parry JM, editors. Mutagenicity Testing, a Practical Approach. Oxford, England: IRL Press; 1984. p. 137.
34. Chu K.C., Patel K.M., Lin A.H., Tarone R.E., Linhart M.S., Dunkel V.C. Evaluating statistical analysis and reproducibility of microbial mutagenicity assays. Mutat. Res. 85:1981;119-132.
35. Singh N.P., McCoy M.T., Tice R.R., Schneider E.L. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell. Res. 175:1988;184-191.
36. Merk O., Speit G. Detection of crosslinks with the Comet assay in relationship to genotoxicity and cytotoxicity. Environ. Mol. Mutagen. 33:1999;167-172.
37. Tice R.R., Agurell E., Anderson D., Burlinson B., Hartmann A., Kobayashi H., Miyamae Y., Rojas E., Ryu J.-C., Sasaki Y.F. Single cell gel/Comet assay: guideline for in vitro and in vivo genetic toxicology testing. Environ. Mol. Mutagen. 35:2000;206-221.
38. Sutherland J.B. Detoxification of polycyclic aromatic hydrocarbons by fungi. J. Ind. Microbiol. 9:1992;53-62.
39. Singh N.P. Microgels for estimation of DNA strand breaks, DNA protein crosslinks and apoptosis. Mutat. Res. 455:2000;111-127.
40. Hartmann A., Kiskinis E., Fiällmann A., Suter W. Influence of cytotoxicity and compound precipitation on test results in the alkaline Comet assay. Mutat. Res. 497:2001;199-212.
41. Roser S., Poo-Zobel B.-L., Rechkemmer G. Contribution of apoptosis to response in the Comet assay. Mutat. Res. 497:2001;169-175.
42. Henderson L., Wolfreys A., Fedyk J., Bourner C., Windebank S. The ability of the Comet assay to discriminate between genotoxins and cytotoxins. Mutagenesis. 13:1998;89-94.
43. Choucroun P., Gillet D., Dorange G., Sawicki B., Dewitte J.D. Comet assay and early apoptosis. Mutat. Res. 478:2001;89-96.